Dr. John Cush RheumNow
2 years 1 month ago
"Vanishing Fingers" Acro-osteolysis in a patient with Scleroderma and renal failure and bilateral hand pain. Causes of AO include Scleroderma, PsA, hypertrophic osteoarthropathy, skeletal dysplasias, frostbite, Hyperparathyroidism, genetic disorders https://t.co/UwXcw3r6LD https://t.co/bnGiY0i0ot
Dr. John Cush RheumNow
2 years 1 month ago
Difficult to treat RA Approach
https://t.co/2rmlv0kspP https://t.co/6yb5xj8jrn
Dr. John Cush RheumNow
2 years 1 month ago
Norwegian Registry study compared risk of stroke in 2750 RA vs 158 879 w/o RA pts. 7.3 vs 5% (HR 1.36; 1.13, 1.62). RA pts with atrial fibrillation was also elevated (HR 1.25; 1.05, 1.5). RA pts less likely to Rx w/ oral anticoagulants (adj OR 0.88) than non-RA… https://t.co/s20wTKafR8 https://t.co/FPxc5VP4Xh
Dr. John Cush RheumNow
2 years 1 month ago
Study of 4821 pts (age 52 yrs) undergoig EGD - H. pylori infx seen in 2262, w/ long-lasting H Pylori (LLHp) infx in 1043 (21.6%). 6.3% dx w/ aCVD & 4.3% w/ RA. LLHp infection incr risk of aCVS (HR 1.57) & RA (HR 2.63) In RA, LLHp up risk for aCVD (7.89) https://t.co/FNOsEHKVIf https://t.co/dSeJuuuUMQ
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. This week with a focus on fingers and better prescriptive follow through.
Dr. John Cush RheumNow
2 years 1 month ago
Is it possible that Helicobacter pylori (Gm neg) can exacerbate or cause RA? Infx of gastric epithelial cell line w/ H. pylori upregulated the expression of PAD4 and increased PAD4 activity, leading to Helicobacter pylori-induced citrullination? https://t.co/QeE3SmWLLp https://t.co/ZG2tYmdJNx
Dr. John Cush RheumNow
2 years 1 month ago
Singapore study of Autoimmune (AIRD) risk w/ COVID infx compared 104 179 DELTA + pts vs 666 575 PCR neg controls (~80+% Vax) & 375 903 Omicron+ vs 619 379 controls (~75% boosted). Found no signif incr risk of AIRD w/ COVID infx. https://t.co/gXzWdotzvL https://t.co/UsQpwgsyTD
Dr. John Cush RheumNow
2 years 1 month ago
Immunomodulatory Prevention of Uveitis Relapse in Behçet's
The results of a randomised, open-label, head-to-head trial shows that adalimumab was superior to ciclosporin in preventing uveitis relapses in patients with severe Behçet's disease.
https://t.co/12fpuIZFmA https://t.co/iDJJq29JMA
A new chapter may have begun in the exciting story of "immune reset" therapy for difficult-to-treat autoimmune diseases, with a patient with severe refractory lupus obtaining drug-free remission after treatment with an antibody product normally used in multiple myeloma.
Dr. John Cush RheumNow
2 years 1 month ago
Study of 4370 RA pts (26534 PYs) saw 362 MACE (CV) events. RA activity & inflammatory markers assoc w/ MACE risk in bDMARD non-users (not those on bDMARDs). 515 bDMARD vs 3855 non-users (n=3855). Each DAS28-CRP unit incr MACE risk (HR 1.21)https://t.co/lRaHxTHzqe https://t.co/usEiJctVYk
Smolen and colleagues have published a subanalysis of the EXXELERATE study that showed while certolizumab pegol [CZP] concentrations and efficacy was unaffected by high titers of rheumatoid factor (RF), patients treated with adalimumab had a blunted response in the face of high RF titers.
Dr. John Cush RheumNow
2 years 1 month ago
Claims analysis, shows <0.5% of IBD or RA pts developed an invasive fungal infx within 1 year of TNF therapy initiation (. Histoplasmosis was the most common
IBD = 3.3 IFI/100PY
RA = 2.8 IFF/100PY https://t.co/ER9YCxecJT https://t.co/T0UNgB4h6R
Dr. John Cush RheumNow
2 years 1 month ago
Prospective Nurses' Health Study (n 204,175) included 212 w/ incident SLE; ultraprocessed food intake was assoc w/ >50% increased SLE risk & doubled risk for anti-dsDNA Abs. Sugar-/artificially sweetened drinks assoc w/ lupus risk (HR 1.45) https://t.co/jesfsgNvUY https://t.co/KQupBkEcKg
Dr. John Cush RheumNow
2 years 1 month ago
Metanalysis of Social determinants of health and lupus nephritis (31 studies) showed poor LN outcomes were 1.47-fold higher w/ any adverse SDoH. Also multiplicative impact of having two or more adverse SDoH on LN outcomes. https://t.co/4oEuAEgBx1 https://t.co/OkeRzrCXzQ
